KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.96

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Adrien Rousseau, Maryam Karimi, Stefan Michiels, Guilhem Roubaud, Xavier Maldonado, Stephane Supiot, Ray McDermott, Aude Flechon, Bertrand Tombal, Philippe Ronchin, Dominik Berthold, Jean-François Berdah, Gabriel Kacso, Gwenaelle Gravis, Fabio Calabro, Sophie Tartas, Xavier Muracciole, Helene Ribault, Karim Fizazi, Stéphanie Foulon

Eur J Cancer 230 116024

PMID41045691
PMCID-
DOI10.1016/j.ejca.2025.116024
发表日期2025-10-04
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

INTRODUCTION: PEACE-1 is a 2×2 factorial phase III trial evaluating the impact of abiraterone-prednisone and prostate radiotherapy in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC). Abiraterone-prednisone significantly improved overall survival (OS) (hazard ratio (HR)= 0.82 [95 %CI, 0.69-0.98]). In the control arm, men often received an androgen receptor pathway inhibitor (ARPI) - either abiraterone-prednisone or enzalutamide - after progression to castration-resistant disease. The use of active drug beyond progression may improve post-progression survival and thereby attenuate the estimated benefit of early use of this drug in intention-to-treat analyses. METHODS: This post-hoc analysis applied three statistical methods to estimate an adjusted HR accounting for abiraterone-prednisone use beyond progression: Two-Stage Estimation (TSE), Inverse Probability of Censoring Weighting (IPCW) and Rank-Preserving Structural Failure Time Models (RPSFTM). RESULTS: Among 589 patients randomised to the control arm, 183 received abiraterone-prednisone after disease progression. Compared with patients who did not, these men had higher PSA at diagnosis, higher tumour burden, more bone metastases, and were more likely to have received docetaxel for mCSPC. Experiencing biochemical progression was found to be a risk factor for 2nd line abiraterone use. The HR for OS adjusted by RPSFTM, IPCW, and TSE were 0.79 [0.64-0.98], 0.75 [0.62-0.92], and 0.82 [0.67-0.98], respectively. Sensitivity analyses adjusting for ARPI cross-over (abiraterone-prednisone or enzalutamide) yielded consistent results. CONCLUSIONS: This analysis confirms the survival benefit related to upfront abiraterone-prednisone use for patients with de novo mCSPC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。